Yunn Yi Chen

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast
    Yunn Yi Chen
    Department of Pathology, University of California San Francisco, California 94143, USA
    Am J Surg Pathol 33:1683-94. 2009
  2. pmc Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ
    Yunn Yi Chen
    Department of Surgery, University of California San Francisco, San Francisco, USA
    BMC Cancer 9:285. 2009
  3. doi request reprint FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast
    Aseem Lal
    Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    Breast Cancer Res Treat 139:381-90. 2013
  4. ncbi request reprint Magnetic resonance imaging captures the biology of ductal carcinoma in situ
    Laura J Esserman
    Department of Surgery, University of California, San Francisco, USA
    J Clin Oncol 24:4603-10. 2006
  5. ncbi request reprint Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis
    James E Korkola
    Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143 0808, USA
    Cancer Res 63:7167-75. 2003
  6. pmc Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression
    Junko Suzuki
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    Clin Cancer Res 15:3163-71. 2009
  7. ncbi request reprint Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors
    Chrystal V Wa
    Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA
    Mod Pathol 18:591-7. 2005
  8. doi request reprint Genomic alterations and phenotype of large compared to small high-grade ductal carcinoma in situ
    E Shelley Hwang
    Department of Surgery, University of California San Francisco, San Francisco, CA 94143 1710, USA
    Hum Pathol 42:1467-75. 2011
  9. doi request reprint D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma
    Joseph T Rabban
    Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA
    Hum Pathol 39:175-83. 2008
  10. pmc Identification of a robust gene signature that predicts breast cancer outcome in independent data sets
    James E Korkola
    Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA
    BMC Cancer 7:61. 2007

Collaborators

Detail Information

Publications21

  1. pmc Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast
    Yunn Yi Chen
    Department of Pathology, University of California San Francisco, California 94143, USA
    Am J Surg Pathol 33:1683-94. 2009
    ..However, clinical follow-up studies will be required to define the natural history and most appropriate management of these lesions...
  2. pmc Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ
    Yunn Yi Chen
    Department of Surgery, University of California San Francisco, San Francisco, USA
    BMC Cancer 9:285. 2009
    ....
  3. doi request reprint FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast
    Aseem Lal
    Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    Breast Cancer Res Treat 139:381-90. 2013
    ..013 for normal, p = 0.001 for IDC). These findings implicate both Treg infiltration and up-regulated epithelial FOXP3 expression in breast cancer progression...
  4. ncbi request reprint Magnetic resonance imaging captures the biology of ductal carcinoma in situ
    Laura J Esserman
    Department of Surgery, University of California, San Francisco, USA
    J Clin Oncol 24:4603-10. 2006
    ..We investigated whether MRI features of DCIS reflect differences in biology and pathology...
  5. ncbi request reprint Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis
    James E Korkola
    Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143 0808, USA
    Cancer Res 63:7167-75. 2003
    ..In conclusion, specific changes in gene expression distinguish lobular from ductal breast carcinomas. These genes may be important in understanding the basis of phenotypic differences among breast cancers...
  6. pmc Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression
    Junko Suzuki
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    Clin Cancer Res 15:3163-71. 2009
    ..However, HDAC expression and protein acetylation have not been studied in the context of breast cancer progression...
  7. ncbi request reprint Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors
    Chrystal V Wa
    Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA
    Mod Pathol 18:591-7. 2005
    ..We conclude that genetic analysis by array-based CGH can clearly elucidate the relationships between multiple tumors and may potentially serve as an important clinical tool...
  8. doi request reprint Genomic alterations and phenotype of large compared to small high-grade ductal carcinoma in situ
    E Shelley Hwang
    Department of Surgery, University of California San Francisco, San Francisco, CA 94143 1710, USA
    Hum Pathol 42:1467-75. 2011
    ..Interestingly, larger tumors showed some molecular features associated with better prognosis. A more thorough evaluation of these differences could help identify the likelihood of recurrence or progression for in situ lesions...
  9. doi request reprint D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma
    Joseph T Rabban
    Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA
    Hum Pathol 39:175-83. 2008
    ..We recommend that myoepithelial markers be used in conjunction with D2-40 to distinguish solid intralymphatic tumor emboli from solid pattern in situ carcinoma...
  10. pmc Identification of a robust gene signature that predicts breast cancer outcome in independent data sets
    James E Korkola
    Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA
    BMC Cancer 7:61. 2007
    ..Breast cancer is a heterogeneous disease, presenting with a wide range of histologic, clinical, and genetic features. Microarray technology has shown promise in predicting outcome in these patients...
  11. ncbi request reprint Increased beta1 integrin is associated with decreased survival in invasive breast cancer
    Evelyn S Yao
    Department of Radiation Oncology, Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1708, and Lawrence Berkeley National Laboratory, Berkeley, California, USA
    Cancer Res 67:659-64. 2007
    ....
  12. pmc CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues
    Rosa Anna DeFilippis
    Department of Pathology, Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Cancer Discov 2:826-39. 2012
    ..Levels of CD36 and extent of mammographic density are both modifiable factors that provide potential for intervention...
  13. ncbi request reprint Fibroepithelial lesions with cellular stroma on breast core needle biopsy: are there predictors of outcome on surgical excision?
    Timothy W Jacobs
    Department of Pathology, Virginia Mason Medical Center, Seattle, WA 98101, USA
    Am J Clin Pathol 124:342-54. 2005
    ..Assessment of stromal cellularity, mitoses, and proliferation indices might help determine the probability of phyllodes tumor occurring and guide management of these cases...
  14. ncbi request reprint Array-based comparative genomic hybridization of ductal carcinoma in situ and synchronous invasive lobular cancer
    Sarah J Nyante
    Department of Surgery, University of California San Francisco, 94115, USA
    Hum Pathol 35:759-63. 2004
    ..The following case illustrates how array CGH may be used to better understand whether synchronous neoplasms share a common origin...
  15. ncbi request reprint Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ
    Anjali S Kumar
    Department of Surgery, University of California San Francisco, San Francisco, CA, USA
    Am J Surg 192:520-4. 2006
    ..We investigated the pathologic and biologic characteristics of false positive enhancement by breast MRI...
  16. pmc Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI
    Nima Nabavizadeh
    Department of Radiation Oncology, University of California, San Francisco Comprehensive Cancer Center, 1600 Divisadero Street H1031, San Francisco, CA 94143 1708, USA
    Integr Biol (Camb) 3:490-6. 2011
    ..Identification of a cancer-associated stroma may be further developed to help guide local therapy to reduce recurrence and morbidity in breast cancer patients...
  17. ncbi request reprint Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential diagnostic pitfalls using myoepithelial markers
    Joseph T Rabban
    Department of Pathology, University of California, San Francisco, CA 94143, USA
    Mod Pathol 19:1351-7. 2006
    ..Reliance on p63 or smooth muscle actin alone poses a potential diagnostic pitfall in evaluating cribriform breast lesions...
  18. doi request reprint Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease
    Joseph T Rabban
    Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA
    Am J Surg Pathol 33:256-63. 2009
    ..D2-40 immunostaining is useful in this setting. Current staging criteria should be clarified to define whether extensive intralymphatic tumor should be incorporated in tumor stage assignment...
  19. pmc Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors
    Mona L Gauthier
    Department of Pathology, University of California, San Francisco, CA 94143, USA
    Cancer Cell 12:479-91. 2007
    ..Assessment of these biomarkers in DCIS begins to allow prediction of tumor formation years before it actually occurs...
  20. pmc Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657
    Laura J Esserman
    Breast Care Center, University of California at San Francisco, 1600 Divisadero St, 2nd Floor, Box 1710, San Francisco, CA 94115, USA
    J Clin Oncol 30:3242-9. 2012
    ....
  21. ncbi request reprint Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus
    Michael Torbenson
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Am J Surg Pathol 30:508-13. 2006
    ..We conclude that glycogenic hepatopathy can cause hepatomegaly and significant transaminase elevations in individuals with type I diabetes mellitus. The pathology is distinct from steatohepatitis...